Aurinia Pharmaceuticals Inc

1. 01

   9.0 days to cover short interest

   7.8M shares were sold short at the 15 Oct 2026 settlement, 5.8% of the 134.0M shares outstanding; covering them would take 9.0 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

2. 02

   Ahead of SPY, behind its sector fund XLV over 1 year

   1 month: +9.1% (SPY −1.6%, XLV +13.5%). 3 months: +12.6% (SPY −0.4%, XLV +15.5%). 1 year: +19.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: AUPH, SPY and XLV · as of 4 Nov 2026

3. 03

   Above its 50- and 200-day averages

   The 4 Nov 2026 close of $17.11 was 3.8% above its 50-day average ($16.48) and 9.2% above its 200-day average ($15.67). It has closed above the 200-day for 55 sessions, since 19 Aug 2026. The 50-day average crossed above the 200-day on 26 Sep 2024, 528 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

4. 04

   63% of the way up its 52-week range

   Closed at $17.11 on 4 Nov 2026: 11.1% below the 52-week high of $19.25 (24 Jun 2026) and 26.6% above the low of $13.52 (27 Feb 2026).

   Daily price bars, split-adjusted · as of 4 Nov 2026

5. 05

   Volume 1.8× its 30-session average on 4 Nov 2026

   4 Nov 2026 volume of 1.5M shares was 1.8× the average of the 30 sessions before it (826.3K), as the price rose 3.3%. SPY traded 1.5× its own average that session.

   Daily volume against a 30-session baseline · as of 4 Nov 2026

At the 4 Nov 2026 close